New drug clinical data shows promise! TaiRx aiming for international competition, planning for market listing

TaiRx, Inc. has seen promising results from the Phase II preliminary trials of its CVM-1118 new drug for treating neuroendocrine tumors and liver cancer, exceeding expectations. Chairman Lin Chun announced on the 26th that the company is currently advancing in three main directions: international collaboration, frontline drug usage, and the initiation of an Antibody-Drug Conjugate (ADC) drug program, aiming to compete on the global stage.